Literature DB >> 12695253

Surgical ablation of retinal angiomatous proliferation.

J Luigi Borrillo1, Arunan Sivalingam, Adam Martidis, Jay L Federman.   

Abstract

Age-related macular degeneration (AMD) remains the leading cause of visual loss in adults older than 65 years. Retinal angiomatous proliferation (RAP) is a newly recognized manifestation of exudative AMD that has a poor natural history and demonstrated resistance to treatment with conventional laser photocoagulation. A novel surgical technique has been developed in this pilot series that shows promise in the treatment of this subtype of neovascular lesions. Through specific surgical lysis of the feeding arteriole and draining venule of an RAP lesion, improvement in visual acuity has been noted. This has been correlated with resolution of intraretinal edema and flattening of associated pigment epithelial detachment, which was confirmed by fluorescein angiography, optical coherence tomography, and high-speed indocyanine green angiography.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695253     DOI: 10.1001/archopht.121.4.558

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  14 in total

1.  Treatment of recurrent retinal angiomatous proliferation with intravitreal triamcinolone acetonide followed by photodynamic therapy with verteporfin: A retrospective case series.

Authors:  Nicola Cardascia; Claudio Furino; Andrea Ferrara; Francesco Boscia; Giovanni Alessio
Journal:  Curr Ther Res Clin Exp       Date:  2009-06

2.  Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone.

Authors:  Ilse Krebs; Katharina Krepler; Ulrike Stolba; Alexandra Goll; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-03       Impact factor: 3.117

3.  Surgical excision of neovascularization in retinal angiomatous proliferation.

Authors:  Hiroyuki Shimada; Ryuzaburo Mori; Keiko Arai; Akiyuki Kawamura; Mitsuko Yuzawa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-12-17       Impact factor: 3.117

4.  Photodynamic therapy with verteporfin for retinal angiomatous proliferation.

Authors:  Francesco Boscia; Maurizio Battaglia Parodi; Claudio Furino; Michele Reibaldi; Carlo Sborgia
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-09       Impact factor: 3.117

5.  Polypoidal choroidal vasculopathy and retinochoroidal anastomosis in Japanese patients eligible for photodynamic therapy for exudative age-related macular degeneration.

Authors:  Ryo Obata; Yasuo Yanagi; Junko Kami; Hidenori Takahashi; Yuji Inoue; Yasuhiro Tamaki
Journal:  Jpn J Ophthalmol       Date:  2006 Jul-Aug       Impact factor: 2.447

6.  [Intravitreal ranibizumab for the treatment of retinal angiomatous proliferation].

Authors:  J Maaß; D Sandner; E Matthé
Journal:  Ophthalmologe       Date:  2017-06       Impact factor: 1.059

7.  Intravitreal triamcinolone and laser photocoagulation for retinal angiomatous proliferation.

Authors:  T R Krieglstein; A Kampik; M Ulbig
Journal:  Br J Ophthalmol       Date:  2006-08-02       Impact factor: 4.638

8.  Retinal angiomatous proliferation with a cilioretinal artery anastomosis: an unusual presentation.

Authors:  Nicola G Ghazi; Brian P Conway
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-12-17       Impact factor: 3.117

9.  Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano
Journal:  Jpn J Ophthalmol       Date:  2012-12-04       Impact factor: 2.447

10.  Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).

Authors:  Lazaros Konstantinidis; Evangelia Mameletzi; Irmela Mantel; Jean-Antoine Pournaras; Leonidas Zografos; Aude Ambresin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-04-29       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.